KBC Group
VKTX icon

KBC Group’s Viking Therapeutics VKTX Stock Holding History

KBC Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Hold
3,960
– – ﹤0.01% 1161
2026
Q1 		$129K Buy
3,960
+1,030
+35% +$33.1K ﹤0.01% 1175
2025
Q4 		$103K Hold
2,930
– – ﹤0.01% 1256
2025
Q3 		$77K Hold
2,930
– – ﹤0.01% 1432
2025
Q2 		$78K Sell
2,930
-1,354
-32% -$35.6K ﹤0.01% 1370
2025
Q1 		$103K Buy
4,284
+30
+0.7% +$948 ﹤0.01% 1469
2024
Q4 		$171K Buy
4,254
+1,257
+42% +$71.7K ﹤0.01% 1219
2024
Q3 		$190K Buy
2,997
+473
+19% +$27.8K ﹤0.01% 958
2024
Q2 		$134K Buy
2,524
+736
+41% +$48.2K ﹤0.01% 1026
2024
Q1 		$147K Buy
+1,788
New +$79.6K ﹤0.01% 949
2023
Q4 		– Sell
-1,445
Closed -$16K – 1909
2023
Q3 		$16K Buy
+1,445
New +$20.7K ﹤0.01% 1905

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

KBC Group's VKTX Position: Q2 2026 in Review

KBC Group held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 3,960 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1161.

KBC Group first reported a position in VKTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $190K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • KBC Group held 3,960 shares of Viking Therapeutics worth $154K as of Q2 2026.
  • KBC Group left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1161 holding.
  • KBC Group first reported a position in Viking Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's Viking Therapeutics position peaked at $190K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.